Plain-English translation of NCT07495852 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a second-generation travoprost intracameral implant — a small device placed inside the eye to help lower eye pressure in people with glaucoma or ocular hypertension. Researchers want to see how well this implant works compared to daily eye drops, and whether it can help patients manage their eye pressure more effectively over time.
Many people with glaucoma struggle to use eye drops consistently every day, which can make it harder to control eye pressure and prevent vision loss. This medication in implant form is designed to provide steady, long-lasting pressure relief without requiring daily drops.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the new implant (with placebo drops) or continue using timolol eye drops twice daily. The implant group will have a small procedure to place the device and return for an exchange procedure at either month 12 or month 24, depending on which cohort you're in. All participants will have regular follow-up visits over 24 months to monitor eye pressure and safety.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Large-scale testing
Sponsor
Glaukos Corporation
Enrollment target
~510 participants
Started
February 2026
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Director
Glaukos Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.